A Phase 2 Parallel Group Study in Adults with Type 2 Diabetes to evaluate Efficacy and Safety of GL0034

Prior treatment

• Exposure to semaglutide, or other Glucagon-like-peptide 1 receptor (GLP-1R) agonists (including combination products) within 3 months prior to screening
• Any additional oral anti-hyperglycemic drugs beyond metformin and/ or a SGLT-2-inhibitor within 3 months prior to screening

Other illness

• Were diagnosed with type 1 diabetes mellitus
• Had known allergies to GLP-1 analogs, GIP + GLP-1 analogs, glucagon, or related compounds

Lab values

• Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of >5.65 mmol/L at screening and/or Day -1. If participant is on lipid-lowering therapies, doses must be stable for 30 days prior to screening

Other

• Women who are pregnant, nursing, or who plan to become pregnant while in the trial

• Male and female patients 18 years to 70 years (both inclusive) of age on the day of signing informed consent
• Diagnosis of Type 2 diabetes mellitus (T2DM) at least 6 months prior to informed consent
• Have a glycated hemoglobin (HbA1c) value at screening of >= 6.5% and <=8.5% and treated with diet and exercise alone or a stable dose of metformin and/ or a SGLT-2-inhibitor for at least 3 months prior to screening
• Have a body mass index of >=28 to <=50 kilograms per square meter (kg/m²), both are inclusive